Gyre Non Currrent Assets Other from 2010 to 2024
| GYRE Stock | 11.75 1.16 8.99% |
Non Currrent Assets Other | First Reported 2008-03-31 | Previous Quarter 1.3 M | Current Value 38.7 M | Quarterly Volatility 11.2 M |
Check Gyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gyre Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 119.1 M, Gross Profit of 114.3 M or Other Operating Expenses of 189.7 M, as well as many indicators such as Price To Sales Ratio of 13.11, Dividend Yield of 0.0698 or Days Sales Outstanding of 51.47. Gyre financial statements analysis is a perfect complement when working with Gyre Therapeutics Valuation or Volatility modules.
Gyre | Non Currrent Assets Other |
Latest Gyre Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Gyre Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Gyre Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gyre Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Gyre Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | (7,053) | |
| Coefficient Of Variation | (49,865) | |
| Mean Deviation | 1,546,260 | |
| Median | 149,000 | |
| Standard Deviation | 3,517,175 | |
| Sample Variance | 12.4T | |
| Range | 16M | |
| R-Value | (0) | |
| Mean Square Error | 13.3T | |
| R-Squared | 0.000023 | |
| Significance | 0.99 | |
| Slope | (3,749) | |
| Total Sum of Squares | 173.2T |
Gyre Non Currrent Assets Other History
About Gyre Therapeutics Financial Statements
Gyre Therapeutics stakeholders use historical fundamental indicators, such as Gyre Therapeutics' Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Gyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Gyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 4.2 M | 4.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:Check out the analysis of Gyre Therapeutics Correlation against competitors. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.